GERMAN-AUSTRIAN RECOMMENDATIONS FOR HIV1- THERAPY IN PREGNANCY AND IN HIV1-EXPOSED NEWBORN – UPDATE 2008

Common declaration*
of
The German AIDS-society (DAIG)
The Austrian AIDS-society (OEAG)
of the HIV-AIDS competence network
as well as
The Robert-Koch Institute Berlin (RKI)
The German Association of Physicians specialized in HIV Care (DAGNAE)
The German Society of Pediatric and Youth Medicine (DGKJ)
The German AIDS Pediatric Association (PAAD)
The German Society of Obstetrics and Gynecology (DGGG)
The National Reference Center for Retroviruses (NRZ)
German AIDS Assistance (DAH)

Updated by
Dr. med. Bernd Buchholz (University Medical Centre Mannheim, Pediatric Clinic), Dr. med. Matthias Beichert (Mannheim, Gynecology and Obstetrics Practice), Dr. med. Ulrich Marcus (Robert Koch Institute, Berlin), Dr. med. Thomas Grubert, Dr. med. Andrea Gingelmaier (Gynecology Clinic of the Ludwig Maximilians University of Munich) Dr. med. Annette Haberl (HIV-Department, J. W. Goethe-University Hospital, Frankfurt) and Dr. med. Brigitte Schmied (Otto-Wagner Spital, Vienna)

* In July 2008 the following recommendations were sent for discussion per e-mail to the participants/specialists as per particulars given below and to all members of the German AIDS-society (DAIG). The final version was prepared on the occasion of a consensus building conference in Cologne on September 5th 2008.

The specialists included (in alphabetical order):
Beichert M (Mannheim)  Graefe K (Hamburg)  Kästner R (München)  Schaferber A (Berlin)
Bogner J (München)  Groger S (Hamburg)  Köngs C (Frankfurt)  Schlechauf D (Berlin)
Brockmeyer N (Bochum)  Grosch-Wörner I (Berlin)  Korn K (Erlangen)  Schmied B (Wien)
Buchholz B (Mannheim)  Grubert T (Ravensburg)  Kremer H (Miami)  Sonnenberg-Schwan U (München)
Cordes C (Berlin)  Gürtler L (Frankfurt)  Marcus U (Berlin)  Stögerer M (Graz)
Feiterna-Sperling C (Berlin)  Haberl A (Frankfurt)  Nichues T (Krefeld)  Vocks-Hauck M (Berlin)
Funke A-M (Bremen)  Hien S (Mannheim)  Ottinger A (Linz)  von Weizäcker K (Berlin)
Gingelmaier A (München)  Hollwitz B (Hannover)  Reitter A (Frankfurt) 
Abstract:
German-Austrian recommendations for HIV1-therapy in pregnancy - Update 2008

Bernd Buchholz (University Medical Centre Mannheim, Pediatric Clinic), Matthias Beichert (Mannheim, Gynecology and Obstetrics Practice), Ulrich Marcus (Robert Koch Institute, Berlin), Thomas Grubert, Andrea Gieselmaier (Gynecology Clinic of the Ludwig Maximilians University of Munich), Dr. med. Annette Haberl (HIV-Department, J. W. Goethe-University Hospital, Frankfurt), Dr. med. Brigitte Schmied (Otto-Wagner Spital, Wien).

In Germany during the last years about 200-250 HIV1-infected pregnant women delivered a baby each year, a number that is currently increasing. To determine the HIV1-status early in pregnancy voluntary HIV-testing of all pregnant women is recommended in Germany and Austria as part of prenatal care. In those cases, where HIV1-infection was known during pregnancy, since 1995 the rate of vertical transmission of HIV1 was reduced to 1-2%.

This low transmission rate has been achieved by the combination of anti-retroviral therapy of pregnant women, caesarean section scheduled before onset of labour, anti-retroviral post exposition prophylaxis in the newborn and refraining from breast-feeding by the HIV1-infected mother. To keep pace with new results in research, approval of new anti-retroviral drugs and changes in the general treatment recommendations for HIV1-infected adults, in 1998, 2001, 2003 and 2005 an interdisciplinary consensus meeting was held. Gynaecologists, infectious disease specialists, paediatricians, pharmacologists, virologists and members of the German AIDS Hilfe (NGO) were participating in this conference to update the prevention strategies. A fifth update became necessary in 2008. The updating process was started in January 2008 and was terminated in September 2008. The guidelines provide new recommendations on the indication and the starting point for HIV1-therapy in pregnancies without complications, drugs and drug combinations to be used preferably in these pregnancies and updated information on adverse effects of anti-retroviral drugs. Also the procedures for different scenarios and risk constellations in pregnancy have been specified again.

With these current guidelines in Germany and Austria the low rate of vertical HIV1-transmission should be further maintained.

Key words: Pregnancy, HIV-therapy, HIV-status, HIV-testing, anti-retroviral drugs, recommendations

INTRODUCTION

The German-Austrian recommendations for HIV1-therapy in pregnancy reflect the current international knowledge and the experience of German clinical settings specialized in the treatment of HIV1-positive pregnant women.

Even though all constellations, scenarios and contingencies of a pregnancy can not be considered within the scope of these recommendations, they are designed as scientifically-based guidelines. The most important and most frequent questions and problems which doctors, who treat HIV1-positive expectant mothers are facing, irrespective of whether they are experienced in the care for such pregnancies or not, are covered in these guidelines.

The medical measures recommended in these guidelines are helpful for every health care professional, who advises a HIV1-positive pregnant woman. Therefore these recommendations should be available in every delivery room. In case of obstetric emergencies the tables of these recommendations can be used as emergency plan.

It is also urgently recommended, that an HIV post-exposure prophylactic emergency set be kept in stock by the hospital and that all medical personnel involved is informed about indications and procedures related to HIV post-exposure prophylaxis after occupational HIV1-exposure (e.g. following needle prick or knife injuries to the operating surgeon).

Therapeutic recommendations can never replace extensive experience with patients and their specific problems. Therefore antenatal care of HIV1-positive expectant mothers, considering the many uncertainties associated with pregnancy, should be performed in or in cooperation with specialized centers.

Without any medical measures to prevent mother to child transmission of HIV1 up to 40% of the HIV1-exposed newborn are HIV1-infected. In those cases, where HIV1-status of the pregnant women was known during pregnancy, since 1995 the rate of vertical transmission of HIV1 was reduced to 1-2% in Germany and Austria [140]. This low transmission rate has been achieved by the combination of anti-retroviral therapy of pregnant women, caesarean section scheduled before onset of labour, anti-retroviral post exposition prophylaxis in the newborn and refraining from breast-feeding by the HIV1-infected mother.

All measures necessary for the prevention of vertical HIV1-transmission can only be employed, if the HIV1-infection status of the expectant mother is known. Risk factors for an HIV-infection, such as origin from a an HIV epidemic region, current or previous intravenous drug abuse or sexual intercourse with an HIV-infected partner, can not always be identified amongst all pregnant HIV1-infected individuals.

For that reason an HIV antibody test should be offered to every pregnant women together with competent personal counseling in regard to possible consequences in the case of a positive test result (see also in 2007 updated German prenatal care guidelines and the therefore created leaflet “HIV-testing in pregnancy” as information of all pregnant women). If necessary this must be carried out with an interpreter and cultural mediation, even if the patient needs to be referred to a specialized center for this purpose. By German law the explicit approval of the pregnant mother is required for HIV-testing, which routinely consists of an ELISA screening test. A positive test result must be confirmed by Western Blot [1, 2]. If the patient is counself by her gynecologist alone, addresses and telephone numbers of additional experts should be made available to the expectant mother. The personal and medical consequences of any positive test result for the woman should also be discussed in the counseling. Furthermore a competent pediatrician should con-
tribute to the counseling about transmission risks, follow-up tests and the course of HIV-1-infection in a child.

As with many other problems in pregnancy, the welfare of the child must be weighed up against that of the mother when deciding for therapeutic/prophylactic measures against HIV-1.

The goals of interdisciplinary cooperation between general practitioners, obstetricians and pediatricians in the treatment of HIV-1-infected expectant mothers and HIV-1-exposed newborns are: 1) the prevention of mother to child transmission of HIV, and 2) the optimal treatment of pregnant women combined with minimal adverse effects in the expectant mother and in the unborn child.

Mothers with a high viral load and/or low t-helper cell numbers transmit HIV-1 more frequently to their children [3, 4, 5], therefore successful therapy of the mother is also beneficial for the child. Risks for the child that might arise from intrauterine exposure to anti-retroviral combination therapies are still uncertain since data regarding pharmacokinetics, pharmacodynamics, embryotoxicity and fetotoxicity of these drugs are lacking [6, 7, 8, 9, 10, 11, 12, 13].

Basic and clinical research data suggest multiple risk factors which contribute to vertical HIV-1-transmission [3, 4, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]. Combined interventions as described in the following chapters can reduce the HIV-1-transmission rate below 2% [16, 26, 27, 28].

The recommendations for diagnostic and therapeutic procedures given here are based on published study results wherever these were available. Such study results, however, are not available for all practical problems and questions, so that often clinical experience and expert opinions must be resorted to.

Even if the goal of these recommendations is the optimal treatment of mother and child based on the most recent findings, it should be stressed that the decision for the recommended diagnostic and therapeutic measures ultimately must be made in agreement with the expectant mother. This means that a refusal of a recommended diagnostic and/or therapeutic measure must also be respected, wherever the consent of an expectant mother can not be acquired despite adequate counseling.

After a detailed analysis of data and publications, a number of procedures were developed for specific situations. Most common situations and scenarios were considered. For all other situations however, individual decision on a case-by-case basis are necessary.

The following situations were discussed and consensus recommendations were made:

1. Prenatal care
2. Indication for anti-retroviral treatment and therapeutic regimens during pregnancy
   2.1 Indication for anti-retroviral treatment
   2.2 Resistance testing
   2.3. Initial therapeutic regimen
   2.4. Management of HIV-1-positive pregnant women with Hepatitis-co-infection
   2.4.1 Management of HIV-1-positive pregnant women with Hepatitis B virus (HBV) co-infection
   2.4.2 Management of HIV-1-positive pregnant women with Hepatitis C virus (HCV) co-infection
   2.5 Interruption of anti-retroviral therapy during the 1st trimester of the pregnancy
3. HIV-1-transmission prophylaxis with standard risk profile
   4. Risk-adapted transmission prophylaxis
   4.1 Multiple pregnancy, premature labor and premature infants 33rd(+0) - 36th(+6)GW and maternal viral load 3000-10000 HIV-copies/ml before birth
   4.2 Amnion infection syndrome/amnionitis, (premature) rupture of membranes >4h, premature birth <33rd(+0) GW and viral load increase at the end of pregnancy >10 000 HIV copies/ml
   4.3 Incision injury of the child/ aspiration and/or ingestion of blood contaminated amniotic fluid
5. Procedures with incomplete transmission prophylaxis
   5.1 With verified HIV-1-infection
   5.2. Situations with unclear HIV-1-infection status
6. Mode of delivery
7. Postnatal care in the delivery room
8. Postnatal prophylaxis of the newborn
9. Refraining from breast-feeding
10. Postnatal care of the HIV-1-exposed child and preparation of a surveillance register
11. Phone-Hotline, notification of unexpected observations and experiences

| Table 1. Grading of the therapeutic recommendations. |
|----------------------------------|----------------------------------|----------------------------------|
| | I | II | III |
| | On the basis of at least one randomized study with clinical end points * | On the basis of surrogate marker studies | According to expert opinion |
| A Unambiguous recommendation | A I | A II | A III |
| B In general advisable | B I | B II | B III |
| C Justifiable | C I | C II | C III |
| D In general not recommended | D I | D II | D III |
| E Unambiguously not recommended | E I | E II | E III |

* Clinical end point studies for new substances are no longer carried out due to the fact that conditions for licensing by the FDA and the EMEA have changed.
The recommendations were graded as outlined in the German-Austrian guidelines for the anti-retroviral Therapy of HIV1-infection [29]. Unless the results of voting are indicated, the recommendation was agreed upon unanimously.

1. Prenatal Care

Upon diagnosis of HIV1 in a pregnant woman, an interdisciplinary center specialized in HIV care should be contacted immediately. From that point onwards the woman should be treated in close cooperation with the gynecologist familiar to the pregnant women. The gynecologist, who usually treats the women, is primarily recommended to carry out the conventional prenatal care for HIV1-positive pregnant women, according to current antenatal care guidelines, to preserve the bond with the patient's familiar environment. Any other additional care measures should also be fitted in this setting. With the help of a well-planned time scheduling a closely-knit monitoring can be ensured.

Psychosocial care should be provided to each HIV1-positive expectant mother, at the latest in the HIV-specialized centers, and the opportunity to contact women's AIDS self-help groups should also be offered. In the HIV-specialized centers the patients should be fully counseled regarding maternofetal transmission risks, current therapeutic options, the possibility to reduce mother-to-child HIV1-transmission rates, existing residual risks, potential short- and long-term effects of intratertiary exposure to anti-retroviral therapy for the child as well as the necessity of postnatal prophylaxis in the child and of avoiding breast-feeding [30, 31, 32]. Considering the rapidly developing state of knowledge regarding HIV, up to date information is only warranted in such specialized centers. To overcome language barriers the help of interpreters should be obtained wherever necessary to ensure that all information reach the patients.

In co-operation between the general practitioner, the gynecologist, the obstetrician, the pediatrician and the patient, an individual, risk-adapted anti-retroviral treatment or prophylaxis concept corresponding to current German-Austrian guidelines for therapy in pregnancy should be set up. The general practitioner before taking any other prescribed or OTC medications during the pregnancy because of potential interactions with the anti-retroviral therapy (e.g. benzodiazepines).

Especially HIV1-positive pregnant women on methadone substitution or with drug abuse should be informed in detail about drug interactions between these drugs and anti-retroviral therapy/prophylaxis. Without continuous medical evaluation anti-retroviral therapy can lead to withdrawal syndrome, which jeopardize success of anti-retroviral therapy due to lack of adherence.

A comprehensive diagnostic evaluation and therapy for genital infections is also important. Local co-infections such as chlamydiasis, trichomoniasis and bacterial vaginosis amongst others correlate with higher HIV1-transmission risks, especially due to potential induction of premature labor [24]. The following examinations are obligatory: determination of vaginal secretion pH; sampling of a native preparation and micro-

1. HIV in Pregnancy: Umbruchvorlage 15.10.2009 12:31 Uhr Seite 464
Table 1. (Additional) Diagnostic measures during a uncomplicated HIV1 pregnancy.

| Diagnostic measure                                      | Timepoint/ frequency | Reason                                                                 |
|--------------------------------------------------------|----------------------|------------------------------------------------------------------------|
| HIV-screening and if necessary HIV-confirmative test   | - routinely in the 1st trimester in case of unknown HIV1-status; - at the start of the 3rd trimester after negative initial test but continuous risk of infection | Precondition for therapeutic measures to reduce the risk of vertical HIV1-transmission |
| CD4 cell count + viral-load                            | At least every two months | Monitoring the course of the HIV1-infection; Initiation of ART or switchover of ART in case of therapeutic failure Control of the efficacy of the (HA)ART to prevent a high HIV1-viral load at birth |
| HIV1-resistance test                                   | 1. As early as possible before the onset of prophylaxis 2. In case of virological therapy failure during an ART 3. With detectable viral load towards the end of an HIV1-prophylaxis 4. 2-6 weeks after application of a prepartal NVP ultra-short prophylaxis | 1. Exclusion of a primary ZDV resistance [38, 39, 40, 41] 2. According to general therapeutic recommendations for optimizing a therapeutic switchover [29] 3. Registration of any possible resistance induction that might have implications for a future therapy [42] 4. Documentation of a potential resistance induction [43, 44] |
| Blood count (Hemoglobin value)                         | Monthly | Detection of anemia, thrombopenia related to the use of ZDV in particular |
| Oral glucose tolerance test                            | Between 23rd (+0) and 27th (+6) weeks of gestation | Detection of gestation diabetes |
| Lactate level + liver values + γGT + LDH + lipase       | 1. At the start of pregnancy 2. After onset of therapy/prophylaxis 3. In case of clinical symptoms 4. Monthly in the third Trimester | Recommended for detecting lactic acidosis (raised incidence in the 3rd trimester). Discussion of raised lactate and other values in cooperation with clinicians experienced in carrying out and analyzing lactate measurements. |
| pH measurement in the vaginal secretion Native preparation Microbiological culture STD-diagnostics: Chlamydia, gonorrhea, trichomonas, syphilis hepatitis serology Toxoplasmosis screening | At the start of a pregnancy as well as in the 2nd and 3rd trimesters | Recognition and timely treatment of local co-infections that can increase the risk of HIV1-transmission |
| Toxoplasmosis screening                                | At the start of a pregnancy | For the diagnosis of a new infection or a toxoplasmosis reactivation |
| Colposcopy, cytological controls for vulvar, vaginal and cervical dysplasias, HPV-testing | Colposcopy, cytological examination and HPV-testing at the start of a pregnancy; If abnormalities are revealed, colposcopic controls and wherever necessary histological clarification (biopsy) | Increased risk of dysplasia with HIV1-infection [37] |
| Measurement nuchal translucency                         | 10th (+6) – 13th (+6) week of gestation | Estimation of the risk of aneuploidy |
| Sonography, at least DEGUM stage 2                     | 19th (+6) – 22nd (+6) week of gestation | Exclusion of malformations |
biological culturing; STD diagnostics; toxoplasmosis screening at the start of therapy and in the second and third trimester to exclude a reactivation and/or new infection at the end of the pregnancy; a complete hepatitis serology. Urinary tract infections should be excluded e.g. by Uricit examination.

Up to 30% of HIV1-infected women display vulvar, vaginal and cervical dysplasias, which can progress more rapidly to carcinoma as a result of the HIV1-induced immune suppression [37]. For this reason a colposcopic examination should be carried out at the onset of pregnancy in addition to pap smear testing of the cervix and HPV-testing for high-risk-HPV-subtypes. If the colposcopic examination and HPV-testing yield normal results, the next control examination can be scheduled in a postnatal appointment. Any abnormalities must be controlled colposcopically and if necessary histologically (AIII). The perianal region should be examined in addition to the vulva, vagina and cervix, as also recommended for non-pregnant HIV1-infected women.

For all HIV1-infected expectant mothers nuchal translucency/ transparency of fetus should be measured between the 10th (+6) and 13th (+6) weeks of gestation to estimate risks of aneuploidy. Fetal sonography (at least DEGUM stage 2) should be carried out between the 19th (+6) and 22nd (+6) weeks of gestation to screen for fetal malformations.

Invasive prenatal diagnostics should be avoided whenever possible. If there is an urgent indication, it should be performed with consideration of viral load and only under the protection of anti-retroviral therapy/prophylaxis because of the risk of contamination of the amniotic fluid [110,111] (AIII).

If the HIV-status of the mother is unknown and invasive prenatal diagnostic is indicated, an HIV-test should be offered at 6-8 weeks after birth a detailed counseling about contraceptive methods is obligatory.

2. INDICATION FOR ANTI-RETROVIRAL TREATMENT AND THERAPEUTIC REGIMENS DURING PREGNANCY

2.1 INDICATION FOR ANTI-RETROVIRAL TREATMENT

Treatment indications [30] for adult HIV1-patients also apply to pregnant women (but check 3.1b!), i.e. in clinically asymptomatic women the immunological threshold for treatment is reached at a CD4-cell count below 350 CD4+ cells/mm3. It should be noted here that a certain degree of immunosuppression is induced physiologically by a pregnancy [20, 47] so that the CD4-values drop by around 10-20% during every pregnancy. In an HIV1-infected woman, this effect is may be even more pronounced (up to 40%). (AIII)

2.2 RESISTANCE TESTING

In order to ensure the efficacy of anti-retroviral prophylaxis/therapy during pregnancy, testing for pre-existing resistance is generally indicated for every treatment naive pregnant woman before the start of anti-retroviral therapy or - prophylaxis [38, 39] (AIII).

For women who become pregnant during anti-retroviral treatment, German-Austrian guidelines for HIV1-therapy in adults recommend resistance testing (AIII) whenever a virological treatment failure is diagnosed.

If at the end of anti-retroviral HIV1-transmission prophylaxis (determined just before - or directly at the time of birth) viral load is detectable in pregnant women, resistance testing should also be performed in order to document the eventual development of resistance under prophylaxis, so that this can be taken into account if the woman requires anti-retroviral therapy at a later timepoint [41] (AIII).

If nevirapine ultra-short prophylaxis (single maternal dose immediately before birth) is given, resistance testing should be carried out 4-6 weeks after the anti-retroviral medication was stopped (see points 4 and 5) in order to determine, whether resistance against nevirapine has been induced [43,44] (AIII).

2.3. INITIAL THERAPEUTIC REGIMEN (see Table 2)

Apart from the inhibition of viral replication in the mother, a major objective of an optimized initial therapeutic regimen during pregnancy is to combine an effective prophylaxis against HIV1-transmission with the highest possible degree of compatibility for mother and fetus. Restriction of subsequent maternal therapeutic options e.g. because of development of drug resistance should also be avoided.

A standard therapeutic regimen is usually a triple combination including two NRTI + either one (if necessary boosted) protease-inhibitor or + Nevirapin is recommended as an initial maternal therapeutic regimen[29] (AI,II). Efavirenz was excluded due to the reports of cerebral malformations in the newborns of efavirenz-treated pregnant monkeys [45]. Because 3 children with myelomeningoceles and one child with Dandy-Walker-malformation were born to women after treatment with Efavirenz in pregnancy[138], meanwhile Efavirenz was reclassified as FDA pregnancy category D. In addition, nucleoside analogues of particularly high mitochondrial toxicity (i.e. didoxycytidine (ddC), stavudine (D4T) and didanosine(DDI)) should not be given in combination with one another wherever possible, because of the raised risk of a potentially fatal lactate acidosis in the expectant mother [46] (AII).

It has to be considered that with the exception of zidovudine, no anti-retroviral drug has been approved for therapy during pregnancy and that the limited experience until now has not permitted any definitive evaluation of the risks and benefits. When choosing anti-retroviral drugs one must also keep in mind that the pharmacokinetics of each drug group (NRTI, NNRTI+PI) can be altered during pregnancy [48, 49, 50]. Therefore during use of PI and NNRTI in pregnancy drug monitoring is compulsory.

2.4. MANAGEMENT OF HIV1-POSITIVE PREGNANT WOMEN WITH HEPATITIS CO-INFECTION

It is urgently necessary to treat hepatitis-/HIV-co-infected pregnant women in an interdisciplinary setting including an infectious disease specialist.
Table 2. Comments on the initial anti-retroviral combinations/substances.

| Initial combinations and substances | Comment |
|------------------------------------|---------|
| **Nucleoside analogs**<br>for which most experience has been gained | Most clinical experience has been gained with the use of these substances. One additional rationale for application of zidovudine is the metabolization of this drug in the placenta which might contribute to the transmission preventing effect [51,52]. Some cases of lethal mitochondrialopathies were reported in non infected children after maternal zidovudine/lamivudine-therapy [7, 8]. Data about long term toxicity especially carcinogenicity/genotoxicity as a matter of incorporation of nucleoside analogs into DNA [112] are lacking. In case of therapeutic failure changed pharmacokinetics of nucleoside analogs because of pregnancy must be taken into consideration [113]. |
| Zidovudine + Lamivudine (also as Combivir®) | Use of Abacavir only after testing for HLA-B*5701[136] to avoid hypersensitivity reaction. So far no increased rate of malformation in humans [57], but individual reports of malformations [67]. |
| Stavudine + Lamivudine | Caution: raised liver enzymes, more allergic reactions since pharmacokinetics are altered during pregnancy [49]. Increased liver toxicity in pregnancy especially with CD4-counts >250/µl. With longer administration enzyme induction of the cytochrome P450 system and therefore accelerated metabolization of nevirapine not only in the expectant mother but also in the newborn [53]. A single normal dose applied before birth and to the newborn is therefore not sufficient for prophylaxis of HIV-1-transmission, if nevirapine has already been given over a longer period during the course of the pregnancy. |
| **NNRTI** | |
| Nevirapine | |
| **Protease inhibitors**,<br>for which most experience has been accrued [50]: | Because of the poor ability of most PIs to cross the placenta (no or poor data: Fos-Amprenavir [57, 113, 125], Darunavir [57, 113], Tipranavir), no therapeutic levels are to be expected in the fetal compartment [54, 55, 56]. As such, no relevant adverse effect frequency is to be expected amongst the fetuses, but it is still unclear whether therapeutic drug levels in the fetus are necessary or helpful to inhibit vertical HIV-1-transmission. |
| Lopinavir + Ritonavir (=Kaletra®) or Saquinavir (Fortovase®) + Ritonavir | No increased rate of malformations in humans [57, 126] |
| **Alternatives**: | Until now rare published studies about the use in pregnancy [54, 57, 113] but as yet no incidence for unusual or unexpected adverse effects [57]. |
| Nelfinavir | |
| Ritonavir | Contraindicated as a mono-PI because of poor compatibility; can be applied at low doses to boost plasma levels of other PIs. |
| Indinavir + Ritonavir | High number of tablets, relevant side effects [57]. With Indinavir there is an increased need for water uptake to prevent the formation of kidney stones in the mother. |
| **New substances**: | |
| T-20 (fusion inhibitor) | Should only be used in heavily pretreated pregnant women as part of anti-retroviral salvage therapy based on resistance testing. Because of the high molecular weight a transplacental passage is not expected and could so far not proved [121]. Some case reports show no adverse effects [57, 127]. |
| Atazanavir | Insufficient data for use in pregnancy [28, 57, 113], does not cross placenta [127]. |
| Emtricitabin | As yet at the most single case reports [80], no recommendation due to the risk of malformations possible [57]. |
| Fosamprenavir | |
| Tipranavir | |
| Darunavir | |
| Maraviroc | |
| Raltegravir | |
**Table 3.1. Prevention of materno-fetal HIV-1 infection during a normal course of pregnancy.**

| Status of expectant mother: | No ART before pregnancy | ART before pregnancy |
|-----------------------------|-------------------------|---------------------|
| Indication:                | CD4 > 350/µl and HIV-1 RNA < 10,000 HIV copies/ml | CD4 > 350/µl and HIV-1 RNA > 10,000 HIV copies/ml | A) Clinical disease category B + C or B) CD4 < 350/µl |
| Maternal treatment indication | NO | NO | YES | YES |
| Fetal indication for prophylaxis | YES (prophylaxis with standard risk) | YES (prophylaxis with raised maternal transmission risk) | YES | YES |

**Therapy:**

1st–13th week of gestation

| No ART | ART before pregnancy |
|--------|----------------------|
| At least bimonthly monitoring of CD4 + VL. Start of ART in case of urgent maternal treatment indication (see above). Invasive prenatal diagnostics (strictly indicated) only under anti-retroviral therapy/prophylaxis. | A) Immediate initiation of ART. At least bimonthly monitoring of CD4 / VL. Switch of ART in case of therapeutic failure or B) Initiation of ART after week 13, depending on the urgency of the maternal treatment indication (see below). At least bimonthly monitoring of CD4 + VL. Start of the ART before week 13 in case of urgent maternal treatment indication. |

**14th–30th week of gestation**

| Therapy: | Resistance testing to exclude primary ZDV resistance |
|----------|-------------------------------------------------------|
| A) ZDV (AI) 2 x 250 mg/d p.o.  B) HAART (BI) e.g. with ZDV + 3TC + PI/NVP, if possible without EFV or d4T + ddi | |

**Beginning/restart of ART** e.g. with ZDV + 3TC / ddi + PI / NVP / premedication, if possible without EFV or d4T + ddi, At least bimonthly monitoring of CD4 and VL, Change of ART if therapeutic failure occurs.

**37th (+0)–37th (+6) week of gestation**

Primary cesarean section or vaginal delivery, only if viral load < limit of detection shortly before birth and no obstetric risks (for preconditions and special management of vaginal birth see 6.文化艺术). + 1 mg/kg i.v. ZDV from 3h before caesarian until separation, during the first hour a doubled loading-dose, i.e. 2 mg/kg no ZDV if d4T is a component of the maternal therapy.

**Newborn with a complication-free birth process**

| A: ZDV 4 x 2 mg/kg/d p.o. for 2–4 weeks or B: ZDV 4 x 1.5 mg/kg/d i.v. for 10 days |

ZDV, zidovudine; ART, anti-retroviral combination therapy with usually three medications: two nucleosidal reverse transcriptase inhibitors + a protease inhibitor (PI) or nevirapine; 3TC, lamivudine; ddi, didanosine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz; VL, virus load.
2.4.1 Management of HIV1-positive pregnant women with Hepatitis B virus (HBV) co-infection

According to the German-Austrian guidelines for the therapy of HIV1-infection in adults [30] an anti-retroviral three drug regimen including Tenofovir plus FTC or Tenofovir plus FTC, which all three have for antiviral activity for hepatitis B, is also recommended for HIV-positive pregnant women with Hepatitis B co-infection. Because of alarming study results in pregnant animals [135, see also 2.3] Tenofovir should be used with caution in pregnancy. In the special case of HBV co-infection in HIV-positive pregnant women the risk-benefit analysis will more often result in the use of Tenofovir, because of the advantage in therapy of Hepatitis B.

Interferon-alpha and pegylated interferon-alpha are not recommended during pregnancy.

After starting anti-retroviral therapy in pregnancy a HIV/HBV co-infected pregnant women should be monitored at close intervals. Not later than two weeks after start of therapy the first laboratory control has to be performed. Thereafter monthly controls are adequate.

If the anti-retroviral therapy will be ceased after pregnancy (no maternal - but fetal indication for therapy) severe flare-up’s of HBV disease should be taken into account and the close laboratory controls must be continued after birth. In case of an indication for therapy of hepatitis B-infection only, after birth a change in therapy to drugs against HBV with no anti-HIV activity is possible.

All infants born to HBV-infected women should receive hepatitis B immune globulin (HBIG) and initiate the three dose hepatitis B vaccination series within 12 hours.

2.4.2 Management of HIV1-positive pregnant women with Hepatitis C virus (HCV) co-infection

Because maternal HCV-infection increases the risk of vertical HIV-transmission, an effective anti-retroviral combination therapy is recommended for HCV-/HIV-co-infected pregnant women.

An effective anti-retroviral HIV-therapy during pregnancy also reduces mother-to-child-transmission of HCV.

In HIV/HCV co-infected pregnant women laboratory examination should be performed two weeks following initiation of anti-retroviral therapy and then at least monthly.

Pegylated interferon-alpha is not recommended and ribavirin is contraindicated during pregnancy because of teratogenicity (FDA category X).

Decisions concerning the mode of delivery in HIV/HCV co-infected pregnant women should be based on considerations related to HIV infection alone.

2.5. INTERRUPTION OF ANTI-RETROVIRAL THERAPY DURING THE 1ST TRIMESTER OF THE PREGNANCY

The decision to interrupt maternal anti-retroviral therapy in the 1st trimester of pregnancy depends on the individual clinical, immunological and virological status of the pregnant woman as well as the anti-retroviral treatment case history. If the patient was clinically symptomatic before the start of anti-retroviral therapy, or if immunological and/or virological parameters showed an advanced state of immune deficiency and/or a very high risk for rapid disease progression, interruption of therapy is fraught with greater risks for the pregnant women than it is for a clinically asymptomatic woman, whose laboratory parameters might justify the start of an anti-retroviral therapy, but whose clinical status is stable and whose laboratory parameters are no cause for major immediate concern.

It must necessarily mentioned, that up to now all randomized trials of structured treatment interruption/STI versus continuous therapy, especially the SMART-study [139] (interruption of therapy with CD4 >350/µl and restart of therapy with CD4 <250/µl versus continuous therapy), showed a more worse outcome in the STI-group according to cardiovascular disease, opportunistic infections, AIDS, death etc.

Vertical HIV1-Transmission occurs very rarely during the first 12 weeks, and is most common at the end of pregnancy and during birth. Therefore an effective HIV1-transmission prophylaxis does not require anti-retroviral therapy during pregnancy, especially the SMART-study [139] (interruption of therapy with CD4 >350/µl and restart of therapy with CD4 <250/µl versus continuous therapy), showed a more worse outcome in the STI-group according to cardiovascular disease, opportunistic infections, AIDS, death etc.

In contrast, because of a possible long half-life up to 3-4 weeks of NNRTI [141] with a high interindividual variability, simultaneous interruption of an anti-retroviral combination therapy with 2NRTI+1NNRTI (such as efavirenz and nevirapine) results in an temporary monotherapy with a high risk of development of NNRTI-resistance. At present the most safe management of this problem in non-pregnant individuals is to replace the NNRTI by a (boosted) PI and cease this.
Table 3.2. Prevention of vertical HIV1-transmission in case of pregnancy - and birth complications.

| Pregnancy complication: | Complication-free (multiple) pregnancy and viral load shortly before birth < 3 000 HIV copies/ml | Viral load shortly before birth 3 000 -10 000 HIV copies/ml | • Premature labor • premature birth in ≥ 33\(^{\text{th}}\) (+0) - 36\(^{\text{th}}\) (+6) GW | • AIS/amnionitis • premature birth < 33\(^{\text{th}}\) (+0) GW | Viral load increase at the end of a pregnancy > 10 000 HIV copies/ml e.g. because of lacking prepartmental prophylaxis |
|-------------------------|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| HIV1-transmission risk  | Normal                                             | Raised                                          | Very high                                       |                                                  |                                                  |
| Measures in the 24\(^{\text{th}}\) (+0) - 37\(^{\text{th}}\) (+6) week of gestation | Multiple pregnancy: Prophylaxis onset brought forward with ZDV or ART after GW 29\(^{\text{th}}\)(+0) because of the risk of premature birth | Tocolysis, • if necessary antibiotics • RDS-prophylaxis • HAART e.g.: ZDV + 3TC + PI/NVP (if possible no EFV or d4T + ddI) |                                                  |                                                  |                                                  |
| Birth: 37\(^{\text{th}}\) (+0) - 37\(^{\text{th}}\) (+6) week of gestation | (Elective) Primary cesarean section/CS or vaginal delivery (the latter only if viral load < limit of detection shortly before birth and no obstetric risks / for management of vaginal birth see 6) + 1 mg/kg i.v. ZDV starting 3 h before cesarean until birth, during the first hour a doubled loading-dose, i.e. 2 mg/kg | Only (Elective) CS !! + 1 mg/kg i.v. ZDV starting 3 h before cesarean until birth, during the first hour a doubled loading-dose, i.e. 2 mg/kg | If still possible (decision dependent of obstetrical situation) cesarean within 4h after rupture of membranes + 1 mg/kg i.v. ZDV from 3 h before cesarean until birth, during the first hour a doubled loading-dose, i.e. 2 mg/kg | Prepartal 1x 200mg NVP° in addition to the ongoing ZDV prophylaxis or ART ZDV prophylaxis or ART |                                                  |
| Postnatal prophylaxis of the newborn (108): | 4 weeks: Dosing with newborns: ZDV 4x 2mg/kg/d p.o. Refraining from breast-feeding | 6 weeks: A) Dosing with newborns + premature babies ≥ 36th (+0) GW: ZDV 4x 2mg/kg/d p.o. B) Dosing with premature babies < 36th (+0) GW (109): 2x2mg/kg/d p.o. (or 2x 1.5mg/kg i.v.) Dosing with premature babies > 30th (+0) GW: from 3rd week of life increase to 3x 2mg/kg/d p.o. Dosing with premature babies ≤ 30th (+0) GW: from 4\(^{\text{th}}\) week of life: increase to 3x 2mg/kg/d p.o. Refraining from breast-feeding | 6 weeks: ZDV 4x 2mg/kg/d (note premature born dosing) + 3TC 2x 2mg/kg/d* A) with successful prenatal NVP application ° a further NVP dose with the newborn (2mg/kg) at an age of between 48-72h B) If NVP° is not given prepartally, two NVP doses (each 2mg/kg) postnatally to the newborn: 1st Dose as soon as possible after birth, 2nd Dose on the 3rd day of life (cave: because of enzyme induction faster elimination of NVP in the newborn, if NVP was a component of the maternal therapy during pregnancy) Refraining from breast-feeding |                                                  |                                                  |

Birth complications: 
- Incision injury to the child
- Oral intake of bloody amniotic fluid into gastrointestinal or respiratory tract of the newborn

HIV1-transmission risk

Postnatal measures in the newborn: 6 weeks: ZDV 4x 2mg/kg/d (check premature born dosing wherever necessary) + 3TC 2x 2mg/kg/d* 

Two postnatal NVP doses° (each 2mg/kg) to the newborn: 1\(^{\text{st}}\) Dose as soon as possible after birth, 2\(^{\text{nd}}\) Dose on the 3rd day of life (cave: because of enzyme induction faster elimination of NVP in the newborn, if NVP was a component of the maternal therapy during pregnancy) Refraining from breast-feeding

° Beware: if the HIV1-positive expectant mother has been treated for a longer period of time with nevirapine during pregnancy, an enzyme induction may occur that may lead to a more rapid breakdown of nevirapine in the newborn.

ZDV, zidovudine; ART, anti-retroviral combination therapy usually with three medications: two nucleoside reverse transcriptase inhibitors + one protease inhibitor (PI) or nevirapine, 3TC, lamivudine, ddI, didanosine, d4T, stavudine, NVP, nevirapine, EFV, etraviren, AIS, amnion infection syndrome
new anti-retroviral treatment after 4 weeks. As an alternative the 2NRTI are continued over 4 weeks after stopping NNRTI (if possible under monitoring the NNRTI-level via therapeutic drug monitoring) [29, 122]. Because a pregnancy is usually observed not before some weeks after conception, an additional 4 weeks lasting procedure to interrupt a regimen with 2NRTI+NNRTI interferes with the avoidance of these drugs during organogenesis. Therefore a prompt interruption of NNRTI-containing regimens can hardly be arranged in the first 6-8 weeks of gestation (where most organs develop) and therefore cannot be recommended. Nevertheless an interruption of a combination with NNRTI in the remaining weeks should be recommended. Nevertheless an interruption of a combination with NNRTI-containing regimens can hardly be arranged in the first 6-8 weeks of gestation (where drugs during organogenesis. Therefore a prompt interruption of NNRTI-containing regimens can hardly be arranged in the first 6-8 weeks of gestation (where most organs develop) and therefore cannot be recommended. Nevertheless an interruption of a combination with NNRTI in the remaining weeks should be guided by an HIV-experienced infectious disease specialist to minimize the development of drug resistance.

The anti-retroviral treatment should not be resumed before the 13th (+0) week of pregnancy in order to take into account the uncertainties in the exact time of conception.

If a woman under anti-retroviral therapy has planned for a child, a pregnancy test (HCG) should be undertaken very early on. The pregnancy test becomes positive 6-8 days after conception, thus a decision to interrupt anti-retroviral therapy can be made accurately in time. On the other hand because the time until conception cannot be calculated and can last very long an anti-retroviral therapy should never be stopped before conception even when the pregnancy is planned.

If a HIV1-positive women plans to get pregnant, if possible no Efavirenz containing ART should be started or Efavirenz containing regimes should be changed to regimens with other components (for example boosted PI, Nevirapine) in time.

After interruption in the first trimester with the same drugs can be restarted (exceptions: efavirenz, combination of stavudine + didanosine, provided that therapeutic alternatives are available) [45, 46], since resistance development is not to be expected [32, 33] (AI,II,III).

These recommendations also apply if pregnancy is first diagnosed during the course of the 1st trimester.

3. HIV1-TRANSMISSION PROPHYLAXIS WITH STANDARD RISK PROFILE (SEE TABLE 3.1)

Prophylactic scheme (= no maternal treatment indication, criteria see table 3.1!!):

3.1a) Viral load in the expectant mother < 10,000 genome copies/ml:
In this situation two alternative regimens can be used:

I. Zidovudine application from the completed 30th (or 28th) (+0) GW at an oral dose of 2x250 mg.

II. Temporary anti-retroviral combination therapy with 3 drugs (HAART; but if possible no Efavirenz) from week of gestation 30+0 (28+0) until immediately after birth

Comments to opportunity I:
Provided that there is no primary resistance to zidovudine, a reduction of viral load at birth can be achieved under a zidovudine-monoprophylaxis from a low initial virus load. This suffices - particularly in combination with a planned cesarean birth - for minimizing the risk of transmission to the child [5, 71, 72, 124, 131, 132]. The advantage in comparison with HAART is the lower risk of prophylaxis-associated toxicity for mother and child. Because of the short duration of this monoprophylaxis and of the comparatively high resistance barrier of zidovudine the risk of developing a resistance against zidovudine should be very low [68, 115]. In comparison to HAART the risk in monoprophylaxis (provided a good adherence to both regimens) is higher that viral load is not reduced sufficiently until birth.

Comments to opportunity II:
Under a temporary standard anti-retroviral therapy (HAART) from week of gestation 30+0 (28+0) until immediately after birth the low viral load can be decreased under limit of detection at birth with a high probability [5, 71, 130, 131, 132]. Because of the long half life (which can induce resistance during a cessation after birth) and increased toxicity in patients with CD4-cells higher than 250/µl, this prophylactic HAART should not contain Nevirapine. Ideal for prophylaxis are regimens with a (boosted) PI [29]. Provided a good adherence the risk of induction of a drug resistance is lower than in a monoprophylaxis with zidovudine. Disadvantage of a prophylaxis with HAART is the higher drug burden for mother and child, which can lead to more adverse effects and toxicities than in a monoprophylaxis. These complications can reduce adherence and then result in development of drug resistance [114]. On the other hand changed pharmacokinetics of anti-retrovirals in pregnancy (published for Indinavir, for many other anti-retroviral drugs no pharmacokinetic data in pregnancy exist) can induce drug resistance [41, 61, 62, 63, 64, 65, 66, 68, 69, 70, 113].

In the decision to use a monoprophylaxis with zidovudine or HAART in pregnant women with a viral load < 10,000 genome copies/ml also the elevated rate of prematurity under HAART, which increases vertical transmission of HIV, must be taken into account [101, 115, 116].

3.1b) viral load in the expectant mother >10,000 HIV-genome copies /ml:
The risk of vertical transmission is directly proportional to the viral load in the pregnant women. If there is not yet a distinct maternal indication for treatment (CD4 cell count >350/µl), but the viral load is higher than 10,000 virus copies/ml, a temporary anti-retroviral standard combination prophylaxis (without efavirenz) is recommended from GW 30 +0 (or 28 + 0) to immediately after delivery, since a zidovudine monoprophylaxis is not able to reduce the viral load with adequate certainty (raised risk of transmission with VL > 10,000 [5, 62, 71, 72, 73, 74] (AI,II).

In case of a very high viral load (>100 000 HIV-copies/ml) a start of anti-retroviral prophylaxis can considered in GW 28+0. The early start of prophylaxis allows for controls of success of anti-retrovirals at an early stage (e.g. in GW 32+0). If a change of anti-
retroviral prophylaxis is necessary at that timepoint, for the new regimen there is enough time until birth to suppress viral load as much as possible.

3.2 Primary cesarean section, available between 37 (+0) to 37 (+6) gestational week utilizing an operation technique which avoids excessive bleeding, performed rapidly by the most experienced obstetrician [75,76]. The benefit of the elective cesarean section for transmission prophylaxis in patients under an anti-retroviral combination therapy or prophylaxis with a low viral load in the plasma, is not evidenced and is still a matter of dispute (see point 6 for a detailed discussion of the mode of birth) (AI,II).

3.3 Pre- and intra-operative intravenous zidovudine application starting 3 hours before cesarean section (2 mg/kg as a loading-dose for 1 hour followed by 1 mg/kg until the delivery of the child according to the original ACTG 076 protocol), even if zidovudine is not a component of the maternal therapy/prophylaxis during the pregnancy [77] (AI).

3.4 Postnatal zidovudine application for the child over 2-4 weeks orally (2 mg/kg every 6 hours) or 10 days i.e: (1.5 mg/kg every 6 hours) [78] (AI).

Since a higher prevalence of zidovudine-resistant HIV1-strains can be expected in the future [40], the presence of wild-type HIV1 should be confirmed genotypically in the expectant mothers before zidovudine is applied (exclusion of genotypic resistance).

4. RISK-ADAPTED TRANSMISSION PROPHYLAXIS

For birth-related HIV1-transmission risks, HIV1-transmission prophylaxis should be escalated in a risk-adapted manner.

4.1 Multiple pregnancy, premature labor and premature infants 33rd(+0) - 36th(+6) GW and maternal viral load 3 000- 10 000 HIV-copies/ml before birth

Because of the increased risk of premature birth in multiple pregnancies, prophylactic zidovudine application should already be started from the 29th (+ 0) week of gestation (AI,II).

In case of premature labor, anti-retroviral combination prophylaxis should be started immediately (with e.g. zidovudine + lamivudine + PI), if the pregnant women is not yet receiving a combination therapy, if a cesarean birth is not indicated because of immaturity of the baby and if labor can still be stopped (AI,III).

If a premature birth is unavoidable, the procedure described in 4.2 should be followed.

If e.g. because of a premature delivery etc. the viral load of the mother is between 3 000 – 10 000 HIV-copies/ml before birth, the postnatal prophylaxis should be prolonged according to the ACTG 076-study protocol, where zidovudine is applied over 6 weeks orally [14,63]. The newborn should be closely monitored during this prolonged prophylaxis. If problems such as anemia, neutropenia or lactate acidosis occur, benefits and risks of continuing the prophylaxis should be carefully weighed, and in doubt prophylaxis should be discontinued (A/III).

4.2 Amnion infection syndrome/amnionitis, premature rupture of membranes > 4h, premature birth <33rd(+0) GW and viral load increase at the end of pregnancy >10 000 HIV copies/ml

In these obstetric emergency situations the transmission risk is greatly increased [3, 5, 15, 16, 72, 79, 132]. The prepartal part of the prophylaxis should (as long as a standard combination therapy/prophylaxis is not already being given) be intensified by an (additional) dose of nevirapine as long as this is still possible [83].

Postnatally, transmission prophylaxis can also be escalated in the newborn through application of nevirapine in addition to a combination prophylaxis with zidovudine + lamivudine [82, 83, 84]. In this case one dose of nevirapine should be given to the newborn after 72h if the mother has already received one dose prepartally (minimum 2hours before birth). Two doses should be given if the mother did not receive a prepartal dose or if less than two hours have elapsed between nevirapine application to the mother and birth [56, 81, 83]. If two doses are given, the first should be given immediately -and the second within 72h after birth (AI,III).

Under nevirapine ultra short monoprophylaxis (one dose of nevirapine shortly before birth) there is a considerable risk of resistance development in the mother (>20%). To reduce this risk either continuous combination therapy (in the case of treatment indications for the mother) or transient combination therapy - e.g. additional 2 NRTI’s over a period of 1 week after oral nevirapine should be considered as a possible protective measure against resistance development (see also the strategies described under 2.5/therapy interruption). So far no evidence base for this strategy.

2-4 weeks after termination of transient combination therapy or ultra short monoprophylaxis it should be evaluated, whether resistance has been induced by resistance testing.

If the HIV1-positive expectant mother was treated with nevirapine for a longer period during the pregnancy, an enzyme induction might result in the newborn so that a more rapid breakdown of nevirapine occurs [53]. For this reason, with longer nevirapine therapy of expectant mothers during pregnancy, the drug must be applied at higher doses to the newborns (4 mg/kg).

The preferred mode of delivery is immediate cesarean section if the rupture of membranes does not already date back longer than 4 hours. For intervals >4 h (premature) rupture of membranes, no advantage of cesarean section regarding transmission risks can be expected [85]. However, the decision to implement this must be based on obstetric considerations.

Rupture of membranes between the 24th and 28th gestational weeks represents a particularly problematic special case. Steroid induced pulmonary maturation in the unborn is not effective before 24 hours after application and therefore contradicts measures required for preventing HIV1-transmission. In this case the high risk of permanent damage to the child due to lacking
pulmonary maturation and the increased HIV1-transmission rate must be carefully weighed up.

4.3 Incision Injury to the Child/Aspiration and/or Ingestion of Bloody Amniotic Fluid

With an incision injury to the child during caesarian section, or if bloody amniotic fluid can be aspirated from the stomach and/or the lungs, a percutaneous occlusion or a mucosal exposure to virus-containing body fluids must be assumed [23]. This justifies an intensification of the usual standard pediatric prophylaxis to a combination prophylaxis consisting of two NRTI's consistent with post-exposure prophylaxis recommendations for adults [86] (AI). An extended application of nevirapine (exceeding the ultra-short prophylaxis) for post-exposure prophylaxis can not be recommended at this time because of the lack of data regarding pharmacokinetics and safety.

Because of the lack of experience and formal approval of protease-inhibitors and NNRTIs for the therapy of newborns, and because of the dearth of comparative studies on the efficacy of double NRTI and triple drug post-exposure prophylaxis regimens, the recommendations for treatment escalation are limited to measures that have been proven effective and tolerable within the context of mother-to-child transmission prophylaxis. For these reasons the postexpositional prophylaxis of newborn with high risk of HIV-transmission should be limited to two NRTI's combined with one or two doses Nevirapine.

5. Procedures with Incomplete Transmission Prophylaxis

5.1 With Verified HIV1-infection

If despite of a known HIV1-infection no transmission prophylaxis has been carried out until the time of birth, this should be done at the latest during delivery and postnatally. A benefit for the newborn can even be expected with incomplete transmission prophylaxis [63,64,87,88,89]. A combination of a nevirapine ultra-short prophylaxis (one dose prepartally for the mother, one dose postpartally for the newborn or 2 doses postpartally) with a six-week zidovudine or zidovudine + lamivudine application for the newborn is then recommended (AI).

According to data from the HIVNET 012 study, a single dose of nevirapine shortly before birth combined with a single dose given to the newborn within 72 hours of birth is more effective in preventing vertical transmission than the immediate pre- and intrapartal administration of zidovudine combined with a week long postnatal administration of zidovudine to the newborn [87]. (Measures of maternal short time nevirapin prophylaxis see also 4.2)

Zidovudine prophylaxis started within 48 hours after birth according to the ACTG 076 protocol (application over 6 weeks) can still lower the HIV1-transmission rate. In a retrospective US study a transmission rate of 9.3% has been reported with initiation of zidovudine therapy in the first 48 hours after vaginal delivery, as compared to a rate of 18.4% for a later onset of therapy (>48 h). Without any therapy, 26.6% of the children became infected [64].

5.2. Situation with an Unclear HIV1-infection Status

If a patient presents late in her third trimester without HIV-Test and sufficient time remains to perform a screening test (and if necessary a confirmatory test), this should be offered without delay, so that intrapartal and postpartal transmission prophylaxis can be carried out whenever the test proves positive [64].

The HIV-antibody test should be accompanied by competent personal counseling, provided if necessary by an appropriate institution [1,2]. The refusal to undergo HIV-antibody testing must be respected.

In cases when the HIV status of the pregnant women is unknown and there is no time to carry out regular testing and counseling, an HIV-rapid test should be offered and prophylactic measures can be instituted with positive rapid test results. During counseling the pregnant women about HIV-rapid tests, it should considered, that in spite of accurateness of these tests (sensitivity and specificity of HIV-rapid tests achieve results of >99.5%) the probability, that a positive HIV-rapid test is positive in confirmatory tests can be less than 50% in the view of the low prevalence of unknown HIV1-infections in pregnant women (estimated about 50-100 cases per 200.000-300.000 untested pregnant women until 2007). Therefore every positive HIV-rapid test must be confirmed by HIV-Elisa or HIV-Westernblot. If the confirmation fails, all measures to avoid HIV1-transmission must be ceased immediately.

An opportunity to further increase the specificity arises from controlling a positive rapid test finding with a second rapid test procedure. If the second test reports a negative finding, the probability is high that the first test result was false positive.

6. Mode of Delivery

Studies, analyzing HIV1-positive pregnant women and their children before the beginning of the HAART-era, showed a significant reduction of mother-to-child-transmission of HIV1 by a primary caesarean section. Delivery by elective cesarean section (before the onset of labor) resulted in a reduction of the vertical transmission risk by approximately 50%, i.e. in a 8.2% vs. 16.8% risk associated with vaginal birth [76]. Elective Cesarean section should therefore represent an essential component of every prophylactic HIV1-transmission regimen (AI,II). On the other hand some studies which compared healthy pregnant women with HIV1-infected pregnant women showed a higher rate of complications as cause of cesarean section (e.g. higher rates of fever, hematoma and wound infection [117, 118, 139]) in HIV1-positive women. In contrast other studies failed to prove these disadvantages of cesarean section [97, 98, 99, 100].

According to recent examinations the protective effect of cesarean section in HIV1-positive women, who were treated with HAART in pregnancy and whose HIV-viral load was under limit of detection at the end
of pregnancy, seems to be minimal [132, 137, 138]).

Hence a vaginal delivery is arguable under these optimal conditions (HAART in pregnancy, HIV-viral load in pregnancy especially shortly before birth under limit of detection), when it is the request of the pregnant women and no obstetric risks argue against it.

Practical procedure in the delivery room:

Preoperative/ intra-operative i.v. zidovudine therapy of the mother at a dose of 1 mg/kg/h after a loading-dose of 2 mg/kg over 1 hour until delivery still represents a prophylactic measure independently of mode of delivery (AI, AII).

a) The elective, primary cesarian section should be carried out by the most experienced obstetrician available utilizing an operation technique which avoids excessive bleeding, performed between 37 (+0) to 37 (+6) gestational week on a labor-free uterus under i.v. application of zidovudine. Because of lower maternal complications (pneumonia/fever) and the possible early bonding in delivery room a local anesthetic procedure (e.g. spinal anesthesia) is preferably recommended [97].

b) To keep the risk of vertical HIV1-transmission as low as possible during an intended vaginal delivery some special features have to be considered:

Invasive monitoring of the newborn (sampling of microbloodprobes from fetal scalp, scalp electrodes etc.) should not be used. A maybe necessary amniotomy has been performed as late as possible. An operative vaginal delivery should be avoided. Especially in case of protracted labour, abnormal fetal heart rate or suspicion of AIDS/amnionitis etc. the indication/decision for a (secondary) cesarean section should be taken into account generously and earlier as usual.

It should be noted that an increased rate of premature birth has been documented on several studies in mothers treated with an anti-retroviral combination therapy [101]. However, two large American studies [5, 36] failed to find an increased rate of premature birth under HAART. Considering these contradictory findings, in the last trimester special attention must be paid towards women with anti-retroviral combination therapy or other risk factors for premature birth so that a premature birth or other emergency mode of birth under unfavorable conditions can be avoided. This is warranted by frequent antepartum controls in the third trimester and, under certain conditions, early hospitalization.

It is urgently recommended that an HIV post-exposure prophylactic emergency set be kept in stock by the hospital and that all medical personnel involved is informed about an emergency plan including indications and procedures related to HIV post-exposure prophylaxis (PEP) after occupational HIV exposure (e.g. following needle prick or knife injuries to the operating surgeon). For actual German-Austrian PEP guidelines see www.daignet.de under HIV-therapy.

7. CARE OF THE NEWBORN IN THE DELIVERY ROOM

Amniotic fluid can be contaminated with HIV1 by the opening of the amniotic sac during both a spontaneous delivery and a cesarean section. With a vaginal delivery there is also the possibility that virus-contain-
gland involving exsudation of infectious wound secretion/blood contribute to this raised infection rate. The WHO therefore recommends that babies of HIV1-infected mothers should be fed with formula food in industrialized countries with clean drinking water. All HIV1-positive mothers should therefore be urged to avoid breast feeding [103,104,105] (AII).

10. POSTNATAL CARE OF THE HIV1-EXPOSED CHILD AND PREPARATION OF A SURVEILLANCE REGISTER

From the 32nd week of gestation IgG antibodies, including also IgG antibody against HIV1, are transmitted from the mother to the fetus across the placenta. Since the conventional HIV1 test is an antibody test, all, i.e. even non-infected children of HIV1-infected mothers, are serologically HIV1-positive until the maternal antibodies disappear.

Detection of HIV1 during the first two years of life must therefore be completed using HIV1-PCR based methods. It is possible to detect either HIV1-DNA or HIV1-RNA. Up to now it is unclear which test procedure is the more sensitive with respect to the special situation of neonatal infection diagnostics. All positive HIV1 test results should be confirmed as rapidly as possible by a second blood test.

It should be noted that commercially available HIV1-PCR kits do not cover all HIV1-subtypes or mosaic viruses (not subtype B) and may provide false negative results [106]. With an HIV1-positive parent that might be infected with a subtype other than B (especially if the patient originates from outside Western Europe / North America), maternal blood must always be analyzed as a positive sample in addition to the child’s blood (if possible before the onset of an anti-retroviral therapy/prophylaxis of the mother).

If the maternal blood is unambiguously HIV1-positive in the PCR, the result of the HIV1-PCR of the child should also be utilized. If the detection of HIV1-nucleic acids fails with maternal blood (negative or borderline findings), the HIV1-PCR analysis of the child’s blood can not be relied upon. Then, either a special examination must be initiated using subtype-adapted PCR primers in specialized laboratories, or the disappearance of the maternal HIV1-antibody at the end of the 2nd year of life must be waited for in order to reliably exclude an HIV1-infection in the child.

If the HIV1-antibodies in the HIV1-exposed child persist, an HIV1-infection must be assumed. As a matter of definition, HIV1-exposed children are regarded as HIV1-negative if an HIV1-Western blot proves completely negative with normal immunoglobulin concentrations.

Amongst children of HIV1-positive mothers, two negative HIV1-PCR findings are required to exclude an HIV1-infection. The first HIV1-PCR should be performed one month after birth (in the age of 28 days; sensitivity 96%, specificity 99%[129]); the second one after the third month of life, because at this time-point the sensitivity and specificity of the HIV1-PCR is considered to be sufficiently high [107].

With the HIV1-PCR test in the first month of life a high rate of HIV1-infected children can be diagnosed. This is important for starting prophylaxis against Pneumocystis carinii as early as possible (if possible 4-6 weeks after birth where HIV1-transmission has occurred) and the early-life anti-retroviral therapy in the first months of life.

With negative HIV1-PCR findings as well, disappearance of maternal antibodies in HIV1-exposed children should be documented at least once.

It must be stressed here that because of the intrauterine and postnatal exposure of a child to anti-retroviral substances with still unknown long-term consequences, clinical surveillance of the children is indispensable to get aware of any long-term damage.

11. HOTLINE, NOTIFICATION OF UNEXPECTED OBSERVATIONS AND EXPERIENCES

Honorary telephone hotline for problems regarding HIV infection during pregnancy and in HIV1-exposed newborn:

Gynecologic problems: 0178 - 282 0 282
HIV-therapy in pregnancy: 0178 – 673 1661
Pediatric problems: 0178 - 41 21 313

Further updating of the recommendations:
Since only little or even no results or information are available regarding the application of newer drugs or combinations of drugs during pregnancy or in newborns, all physicians involved in this work are urgently invited to inform us of any new or unexpected observations and results, e.g. by notifying us by e-mail at the address given in the “address for correspondence” or by notifying the “anti-retroviral Pregnancy Registry” (APR), the largest register for recording experiences with anti-retroviral substances during pregnancy:

Tel-no.: +1-910-256-0238
Fax: +1-910-256-0637 or +44 1895 825 005
Website: www.APRegistry.com

Acknowledgement: The German version of these guidelines was already published under:

Gemeinsame Erklärung der Deutschen AIDS-Gesellschaft (DAIG); der Österreichischen AIDS-Gesellschaft (OAG); des Kompetenzzentres HIV/AIDS sowie des Robert-Koch-Institutes Berlin (RKI); der Deutschen Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung von HIV- und AIDS-Patienten (DAGA); der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin (DGKJ); der Pädiatrischen Arbeitsgemeinschaft AIDS Deutschland (PAAD); der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG); des Nationalen Referenzzentrums für Retroviren (NRZ); der Deutschen AIDS-Hilfe (DAH)

Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft und bei HIV-exponierten Neugeborenen - Update 2008

Dtsch med Wochenschr 2009; 134: S40-S54
© Georg Thieme Verlag KG Stuttgart New York

We thank Georg Thieme Verlag KG Stuttgart · New York for the allowance for the publication of the English version.
LITERATURE

1. Bundeszentrale für gesundheitliche Aufklärung, Köln: AIDS von A bis Z; Neuauflage 2002

2. Deutsche AIDS-Hilfe e.V.: Der heutige Wissensstand 28. überarbeitete Auflage, 2002

3. Mayaux MJ, Dussaux E, Isopet J et al.: Maternal Virus Load during Pregnancy and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1: The French Perinatal Cohort Studies. J Infect Dis 1997; 175: 172-175

4. Sperling RS, Shapiro DE, Coombs RW et al.: Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. N Engl J Med 1996; 335: 1621-1629

5. Cooper ER, Charurat M, Mofenson L et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. JAIDS 2002; 29:484-494

6. Poirier MC, Divi RL, Al-Harthi L et al.: Long-term mitochondrial dysfunction in HIV-infected but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-1785

7. Barret B, Tardieu M, Rustin P et al.: Persistent mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. JAIDS 2003; 32: 173-183

8. Blanche S, Tardieu M, Rustin P et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-1089

9. Poirier MC, Patterson TA, Slikker Jr. W, Olivero OA: Incorporation of 3’-Azido-3’-Deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. JAIDS 1999; 22: 477-483

10. Meng Q, Walker DM, Olivero OA et al.: Zidovudine-di-danosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 2000; 97: 12667-12671

11. Scalfaro P, Chessa JL, Buchwalder PA et al.: Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med 1998; 24: 247-250

12. European Collaborative Study: Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. JAIDS 2003; 32: 380-387

13. Wahl V: Routinemäßige Gabe von Zidovudin an HIV-infizierte Schwangere. Dt Ärztebl 1995; 92:A-3397-3398

14. Frenkel LM, Cowles MK, Shapiro DE et al.: Analysis of the Maternal Components of the AIDS Clinical Trial Group 076 Zidovudine Regimen in the Prevention of Maternal-Infant HIV-1 Transmission. J Infect Dis 1997; 175: 971-974

15. Landesmann SH, Kalish LA, Burns DN et al.: Obstetrical Factors and The Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. N Engl J Med 1996; 334: 1617-1623

16. Mandelbrot L, Brambilla D, Reichelderfer P et al.: Maternal Immunologic and Virologic Risk Factors for Infant Human Immunodeficiency Virus Type 1 Infection: Findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175: 567-575

18. Wimmer CA, Haffner C, Debus G et al.: Maternal Zidovudine Treatment and the Risk of Transmission of Human Immunodeficiency Virus Type 1 to Infants. J Infect Dis 1997; 175: 567-575

19. The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10: 1675-1681

20. The European Collaborative Study: Immunological markers in HIV-infected pregnant women. AIDS 1997; 11: 1859-1865

21. Tuomala RE, O’Driscoll PT, Bremer JW et al.: Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. JID 2003; 187: 375-384

22. Burns DN, Landesmann SH, Wright, DJ et al.: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175:1206-1210

23. Gaillard P, Verhoeffsede C, Mwanumba F et al.: Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS 2000; 14: 2341-2348

24. Wright TC Jr, Subbarao S, Ellerbrock TV et al.: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001; 184: 279-285

25. Mwanumba F, Gaillard P, Inion I et al.: Placental inflammation and perinatal transmission of HIV-1. JAIDS 2002; 29: 262-269

26. Kind Ch, Rudin Ch, Siegrist C et al.: Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205-210

27. Schafer APA: Die HIV-Infektion in Geburthilfe und Gynäkologie. Gynäkologie 1996; 29:129-137

28. Schafer A, Frieske K, Lauper U et al.: Influence of cesarean section before parturition and antiretroviral prophylaxis on the maternal-fetal transmission of HIV. 12th World AIDS Conference Geneva, June 28-July 3 1998, Poster LB 12466

29. Salzberger B, Marcou U, Viebhaber B et al.: German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res. 2004; 9(11): 491-504

URL: http://www.daignet.de/unterLeitlinien

30. Coll O, Fiore S, Florinda M et al.: Pregnancy and HIV infection: A european consensus on management. AIDS 2002; 16(Supppl 2): S1-18

31. CDC Public Health Service Task Force: Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR 1998; 47/ RR2

32. CDC: Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1998; 47/ RR-S

33. Justman JE, Benning L, Danoff A et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS 2003; 32: 298-302

34. Lorenzi P, Spicher VM, Laubereau B et al. (Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study): Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12(18): F 241-247

35. Wimalasundera RC, Larbalestier N, Smith JH et al.: Zidovudine therapy in pregnancy: the dated European recommendations for the clinical use of zidovudine during pregnancy. J Infect Dis 2000; 182: 205-210

36. ConleyLJ,EllerbrockTV,BushTJetal.: HIV-1infection andrisk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359: 108-113

37. Mandelbrot L, Brambilla D, Reichelderfer P et al.: Maternal Immunologic and Virologic Risk Factors for Infant Human Immunodeficiency Virus Type 1 Infection: Findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175: 567-575

38. Rotok K, Wang H, Seeger J et al.: Transport of Viruses Through Fetal Membranes: An In Vitro Model of Perinatal Transmission. J Med Virology 1998; 54: 313-319

39. The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10: 1675-1681
HIV drug resistance testing. Antivir Ther 2004; 9(6): 829-848.

39. Welles SL, Pitt J, Colgrove R and The Women and Infants Transmission Study Group: HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14:263-271.

40. Duve S, Bornm M, Altman D et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Serocoverver Study. JAIDS 2001; 26: 266-273.

41. Eastman PS, Shapiro DE, Coombs RW et al.: Maternal Viral Genotypic Zidovudine Resistance and Infrequent Zidovudine Therapy to Prevent Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Pediatric Clinical Trial Protocol 076. J Infect Dis 1998; 177: 557-564.

42. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al.: Lamivudine-Zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-2093.

43. Jackson JB, Becker-Pergola G, Guay LA et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111-F115.

44. Eshleman SH, Hoover DR, Chen S et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192(1): 30-36.

45. Suraeva Capsules Product Monograph 1998.

46. BMS Warning Letter, 5 January 2001.

47. Rich KC, Siegel JN, Jennings C et al.: CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis 1993; 172: 1221-1227.

48. Kosel BW, Beckerman KP, Hayashi S et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192(1): 30-36.

49. Mirochnick M, Fenton T, Gagnier P et al.: Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178: 368-374.

50. Wang Y, Livingston E, Patil S, et al.: Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180: 1536-1541.

51. Qian M, Bui T, Ho RJY et al.: Metabolism of 3′-Azido-3′-Deoxythymidine (AZT) in Human Placental Trophoblasts and Hofbauer Cells. Biochemical Pharmacology 1994; 48: 383-389.

52. Agbaria R, Manor E, Barak J et al.: Phosphorylation of 3′-Azidothymidine in maternal and fetal peripheral blood mononuclear cells during gestation and at term. JAIDS 2003; 32: 477-481.

53. Taylor GP, Lyall EGH, Back D et al.: Pharmacological implications of lengthened in-uterus exposure to nevirapine. Lancet 2000; 355: 2134-2135.

54. Marzolini C, Rudin C, Decosterd LA et al.: Transplacentatal passage of protease inhibitors at delivery. AIDS 2002; 16: 889-893.

55. Mirochnick M, Dorenbau M, Holland D et al.: Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21(9): 835-838.

56. Mirochnick M, Dorenbau M, Blanchard S et al.: Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. JAIDS 2003; 33(2): 153-156.

57. Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry International Interim Report for 1 January 1999 through 31 July 2007; Issued Dec 2007 available from url: www.apregistry.com.

58. Larsen WJ: Human Embryology. New York: Churchill Livingstone, 1993.

59. Wilson JD, Frazer FC (Hrsg.): Handbook of Teratology, Vol. I. New York: Plenum Press, 1977.

60. Spielmann H, Steinhoff R, Schafer C et al.: Arzneiverordnung in Schwangerschaft und Stillzeit. Sp. Aufl., Stuttgart, Gustav Fischer, 1998.

61. Connor EM, Sperling RS, Geller R et al.: Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. N Engl J Med 1994; 331:1173-1180.

62. Chuaichoowong R, Shaffer N, Sirwasin W et al.: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Inf Dis 2000; 181: 99-106.

63. Lallemant M, Jourdain G, Le Coeur S et al.: A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1 for perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409-1414.

64. Mbori-Ngacha D, Richardson BA, Overbaugh J et al.: Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments. J Virol 2003; 77: 7702-7705.

65. Elkpani RA, Nkengasong JN, Shibli T et al.: Changes in plasma HIV-1 RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002; 16: 625-630.

66. Sabbatini F, Prati F, Borghi V et al.: Congenital pylectasis in children born from mothers on Tenovir containing therapy during pregnancy: report of two cases. Infection 2007; 35: 474-476.

67. Bardelegue AD, Shapiro DE, Mofenson LM et al.: Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. JAIDS 2003; 32: 170-181.

68. Clarke JR, Braganza R, Mirza A et al.: Rapid development of genotype resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59:364-368.

69. O’Sullivan M, Boyer P, Scott G et al.: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510-1516.

70. Garcia PM, Kalish LA, Pitt J et al.: Maternal levels of plasma zidovudine resistance virus type 1 RNA and the risk of perinatal transmission. N Eng J Med 1999; 341: 394-402.

71. Mofenson LM, Lambart JS, Steichn ER et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Eng J Med 1999; 341: 385-393.

72. The European Collaborative Study: Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13: 1377-85.

73. Shaffer N, Roongsawathong A, Sirwasin W et al.: Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Inf Dis 1999; 179: 590-599.

74. Semprini AE: An international randomised trial of mode of delivery in HIV infected women. 12th World AIDS
1. HIV in Pregnancy: Umbruchvorlage  15.10.2009  12:31 Uhr  Seite 478

85. Garcia-Tejedor A, Perales A, Maiques V: Duration of rup-
87. Guay LA, Musoke P, Fleming T et al: Intrapartum and
86. Deutsch-Österreichische Empfehlungen zur postexposi-
83. Lallemant M, Jourdain G, LeCoeur S et al: Perinatal HIV
88. Moodley D, Moodley J, Coovadia H et al: A multicenter
89. Flys T, Nissley DV, Claasen CW et al: Sensitive drug-re-
76. The International Perinatal HIV Group: The mode of de-
82. Taha TE, Kumwenda NI, Hoover DR et al: Nevirapine
77. CDC: Recommendations of the U-S. Public Health Ser-
80. Wensing MJ, Boucher CAB, van Kasteren M et al: Pre-
79. Burns DN, Landesman S, Muenz LR et al: Cigarette
81. Stringer JSA, Sinkala M, Chapman V et al: Timing of the
90. Marcus U: AIDS und HIV-Infektionen bei Frauen und
91. Shapiro D, Tuomala R, Samelson R et al. Abstract 12953,
92. Ioannidis JPA, Abrams EJ, Ammann A et al: CM: Perina-
by pregnant women with RNA virus loads <1000
93. Mandelbrot L, Burgard M, Teglas J-P et al: Frequent de-
94. Debiaggi M, Zara F, Spinillo A et al: Viral excretion in
eircovicaginal secretions of HIV-1-infected women re-
95. Ellerbrock TV, Lennox JL, Clancy KA et al: Cellular
96. Si-Mohamed A, Kazatchkine MD, Goujon C et al: Sele-
97. Avidan MS, Groves P, Blett M et al: Low complication
98. Read J, Tuomala R, Kpagese M et al: Mode of delivery
99. Rodriguez EJ, Spann C, Jamieson D et al: Postoperative
100. Watts DH, Lambert JS, Stichm ER et al: Complications
101. European Collaborative Study and the Swiss Mother +
102. Nduati R, John G, Mbori-Ngacha D et al: Effect of
103. Van de Perre P: Transmission of human immunodefi-
104. Nduati RW, John GC, Richardson BA et al: Human im-
105. Thiry L, Spencer-Goldberger S, Jonckheer T et al: Isola-
106. Haas J, Geiss M, Böhler T et al: False-negative poly-
107. Rossi P, et al: Early diagnosis of HIV infection in in-
108. CENTERS OF DISEASE CONTROL: Guidelines for
109. Capparelli EV, Mirochnick M, Dankner WM et al: Pedi-
110. Maiques V, Garcia-Tejedor A, Perales A et al: HIV de-
111. Davies G, Wilson RD, Deslets V et al: Society of Ob-
112. Conference Geneva, June 28-July 3 1998, Poster LB
113. Mandelbrot L, Burgard M, Teglas J-P et al: Frequent de-
114. Debiaggi M, Zara F, Spinillo A et al: Viral excretion in
eircovicaginal secretions of HIV-1-infected women re-
115. Avidan MS, Groves P, Blett M et al: Low complication
116. Read J, Tuomala R, Kpagese M et al: Mode of delivery
93. Mandelbrot L, Burgard M, Teglas J-P et al: Frequent de-
94. Debiaggi M, Zara F, Spinillo A et al: Viral excretion in
eircovicaginal secretions of HIV-1-infected women re-
95. Ellerbrock TV, Lennox JL, Clancy KA et al: Cellular
96. Si-Mohamed A, Kazatchkine MD, Goujon C et al: Sele-
97. Avidan MS, Groves P, Blett M et al: Low complication
98. Read J, Tuomala R, Kpagese M et al: Mode of delivery
and women with hepatitis B, hepatitis C or human immunodeficiency virus. J Obstet Gynaecol Can 2003; 25(2): 145-148, 149-152

110. Poirier MC, Olivero OA, Walker DM et al: Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004; 199(2): 151-161

111. Mirandack M, Capparelli F et al: Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43(15): 1071-1087

112. Lyons FE, Coughlan S, Byrne CM et al: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19(7): 63-67

113. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr. 2002, 30(2): 216-29.

114. Thorne C, Patel D, Newell ML: Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18(17): 2337-2339

115. Fiore SR, Newell ML, Thorne C: European HIV in Obstetrics Group: Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS 2004; 18(6): 933-938

116. Marcollet A, Goffinet F, Firtion G et al: Differences in child morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002; 186(4): 784-789

117. Kovaes A, Wasserman SS, Burns D et al: DARTI Study Group; WHIS Study Group: Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358(9293): 1593-1601

118. Fiore JR, Sulgoi B, Saracino A et al: Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17(15): 2169-2176

119. Brennan-Benson p, Pakianathan M, Rice P et al: Enfuviritide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross placenta. AIDS 2006; 20: 297-299

120. Chai ML, Dahis F, Elouevi D et al: Addition of 3 Days of ZDV+3TC Postpartum to a Short Course of ZDV+3TC and Single-dose NVP Provides Low Rate of NVP Resistance Mutations and High Efficacy in Preventing Peri-partum HIV-1 Transmission: ANRS DITRAME Plus, Abidjan, Côte d’Ivoire, 12th CROI, Boston 2005, Abstr. 72.B

121. Ripamonti D, Cattaneo D, Maggiolo F et al: Atazanavir plus low-dose ritonavir in pregnancy : pharmacokinetics and placental transfer. AIDS 2007; 21 : 2409-2415

122. Ioannidis JP, Contopoulos-Ioannidis DG: Maternal viral load and the risk of perinatal transmission of HIV-1. N Engl J Med. 1999; 341(22): 1698-1700

123. Chappuy H, Treuyer JM, Rey E et al: Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004; 191(2): 558-562

124. Feiterna-Sperling C, Piening T, Casteleyn S: Use of protease inhibitor associated resistance. J Med Virol 2005; 77(2): 164-172

125. Feiterna-Sperling C, Piening T, Casteleyn S: Use of protease inhibitor associated resistance. J Med Virol 2005; 77(2): 164-172

126. Feiterna-Sperling C, Piening T, Casteleyn S: Use of protease inhibitor associated resistance. J Med Virol 2005; 77(2): 164-172

127. Meyohas MC, Lacombe K, Carbonne B et al: Enfuviritide patch administration in unlabeled women with virological breakthrough. AIDS 2004; 18(14): 1966-1968

128. Morris A, Juethner S, Theroux E: Atazanavir use in pregnancy. Third International AIDS Society Conference on HIV Pathogenesis and Therapy, Rio, poster presentation TuPe5.2p01, 2005.

129. Dunn DT, Brandt CD, Kirvine A et al: The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995; 9(9): F7-F11

130. Chaisiwattana P, Chephaibhikul K, Chalermeokchaoenkit A et al: Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission in Thailand. Clin Infect Dis 2002 35(11): 1405-1413

131. European collaborative study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001 15(6): 761-770

132. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 40(3): 458-465

133. Ananworanich J, Sangphoe U, Hill A et al: Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J AIDS 2005; 39(5): 523-529

134. Pellegrin I, Thiebaut R, Blanco P et al: Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4(+) cells/microl? Impact on immunovirological parameters. J Med Virol 2005; 77(2): 164-172

135. Tarantal AF, Marthas ML, Shaw JP et al: Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20: 323-333.

136. Hughes S, Hughes A, Brothers C et al on behalf of the CNA100630 Study Team. PREDICT-1 (CNA100630): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2007 May 29; [Epub ahead of print]

137. Warszawski J, Tubiana R, Le Chenadec J et al. Mother to child HIV transmission despite antiretroviral therapy in the ARNS French Perinatal Cohort: AIDS 2008; 22: 289-299

138. Mofenson LM. Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care. 2005; 17(2): 17.

139. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman M, Lloso M, Markowitz W, Neumann J, Phillips A, Rappoport C. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 355(22): 2283-96

140. Gingelmaier A, Hollwitz B, Casteleyn S et al. Schwanplus lipozid in pregnancy : pharmacokinetics and placental transfer. AIDS 2007; 21 : 2409-2415

141. Ioannidis JP, Contopoulos-Ioannidis DG: Maternal viral load and the risk of perinatal transmission of HIV-1. N Engl J Med. 1999; 341(22): 1698-1700

142. Chappuy H, Treuyer JM, Rey E et al: Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004; 191(2): 558-562

143. Feiterna-Sperling C, Piening T, Casteleyn S: Use of lopinavir (LPV/r) during pregnancy Eur J Med Res 10 Supplement II, S. 89 P161.

144. Meyohas MC, Lacombe K, Carbonne B et al: Enfuviritide tablet administration at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 2004; 18(14): 1966-1968

145. Morris A, Juethner S, Theroux E: Atazanavir use in pregnancy. Third International AIDS Society Conference on HIV Pathogenesis and Therapy, Rio, poster presentation TuPe5.2p01, 2005.